Eton Pharmaceuticals, Inc. reported $106M of revenue over the trailing twelve months, +81% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $106M (to Q2 2026). Net income: $13M, trailing twelve months to Q2 2026. Free cash flow: $15M, trailing twelve months to Q2 2026. Operating margin: 12%, trailing twelve months to Q2 2026.

ETONEton Pharmaceuticals, Inc.

Healthcare

$54.73+159% 1Y

$54.73

$14.3552 weeks$64.38

ETON as reported

Eton Pharmaceuticals, Inc. reported $106M of revenue over the trailing twelve months, +81% on the year before. 10 reported series are charted on this page, each one as filed.

$106M

Revenue, trailing twelve months · to Q2 2026 · +81% against the twelve months before

Net income: $13M
Net income · −407% year on year · trailing twelve months to Q2 2026
Free cash flow: $15M
Free cash flow · +20% year on year · trailing twelve months to Q2 2026
Operating margin: 12%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ETON, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$106M	+81%	Q2 2026
Net income	$13M	−407%	Q2 2026
EPS	−$0.45	n/a	Q3 2021 · 19 quarters behind
Gross margin	56%	n/a	Q2 2026
Operating margin	12%	n/a	Q2 2026
Net margin	8.9%	n/a	Q2 2026
ROE	−6.0%	n/a	Q2 2026
ROA	−0.49%	n/a	Q2 2026
ROIC	4.0%	n/a	Q2 2026
Free cash flow	$15M	+20%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.